In this exclusive series of articles, David Alain Wohl, M.D., calls attention to 10 developments that have tremendous short-term implications for our day-to-day efforts to improve HIV prevention, treatment, patient care, and policy in the U.S., and analyzes each development with his trademark wit and clinical savvy.
While we remain uncertain about the precise level of interaction (if any) between HIV and SARS-CoV-2 on a pathophysiological level, the pandemic’s disruption of HIV care is irrefutable.
A new report from the CDC highlights encouraging trends in death rates among people with HIV in the U.S., and is explicit in associating them with strong and concerted public health interventions.
Given the decline in mortality among people living with HIV in the U.S., it’s no surprise that the difference in life expectancy between those with and without the virus is shrinking. But the disparities that remain are striking.
A reasonably understandable initial response to this important study could be “WTF”—but the forces that conspire to harm people of color and people living in poverty are persistent and intransigent.
Given the differences we’ve seen among disparate subgroups, it is highly likely that there are genetic influences on the amount of weight people gain on certain HIV therapies, argues David Wohl, M.D.
Doctors contemplate the role of housing in health care as people with HIV grow older, but are often poor.
Will a given development in HIV make a difference in the clinic? Will it change practice? Is this something I should know if I take care of people living with HIV? The answer to each of these must be yes for the story to make the list.
Although you may not have known -- or even heard of -- Charles van der Horst, his DNA is woven into the cloth of HIV care and research.
The vaccine for human papillomavirus got a bad rap when it debuted. And yet time has shown it's very effective in reducing cancers linked to HPV.